See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter ↵ to review claims
Explore by Goal
"Be less curious about people and more curious about ideas."
- Marie Curie
Quick Explanation
Copied
Alberto Durán-Peña: evidence-oriented oncology/neurology reviewer
From the provided author record, Durán-Peña’s visible impact clusters in neuro-oncology topics (glioblastoma, glioma biomarkers, neuro-oncology epilepsy), with multiple highly cited reviews such as seizure prognosis in brain tumors and circulating biomarkers in glioblastoma .
Long Explanation
Author Review — Alberto Duran-Peña (Durán-Peña)
Science-strength critique focused on biological/medical evidence quality, rigor, and interpretability (April 29, 2026 snapshot).
What I can and cannot verify from your input
Verified with DOIs: several concrete works are identifiable from your OpenAlex-derived record (examples cited below).
Not fully verifiable: the three French-titled papers you listed include no DOI/venue/year in your prompt, so I cannot rigorously evaluate them without additional bibliographic metadata.
Important: citation metrics (h-index, total citations, works_count) are taken from the author snapshot you provided in the prompt (not re-computed from a source I can cite with a DOI).
1) Bibliometric signals (from your provided snapshot)
Critical note: metrics like h-index and cited_by_count are not direct measures of rigor for any specific paper. They are consistent with visibility (often reviews have higher citation rates) and can be influenced by field size, review demand, and citation practices.
2) Output volume over time (works_count + OA/total) — from your provided counts_by_year
Interpretation (skeptical): a peak year can reflect pipeline, collaborations, and journal/editorial opportunities—not necessarily changing scientific rigor.
3) Representative cited works (with DOI) — what the evidence looks like
Rigor strengths: reviews can consolidate heterogeneous clinical data, highlight effect modifiers, and set practical decision frameworks.
Rigor risks: review-level evidence quality depends on literature search transparency, inclusion/exclusion criteria, risk-of-bias handling, and whether claims are supported by higher-level studies rather than narrative inference.
Rigor strengths: explicitly framing methodological challenges is useful for interpretability and future study design.
Rigor risks (common in biomarker reviews): biomarker performance can be inflated by pre-analytical variability, small sample sizes, and retrospective validation; review conclusions often need calibration against systematic reviews/meta-analyses.
Radiology/diagnostic “practical approach” review for enhancing lesions
3.2 Clinical research signal: retrospective cohorts
Hypofractionated/elderly glioblastoma radiation context (example from your record: related retrospective framing)
(No DOI provided for the specific French-titled item you listed; therefore I’m not scoring its rigor here.)
Older patients (≥80) with glioblastoma: role of irradiation — retrospective cohort
Rigor strengths: may capture real-world patterns of care.
Rigor risks: retrospective designs are vulnerable to confounding by indication (health status drives treatment choice), missingness, and selection bias—so causal language must be conservative.
4) Topic specialization map (from your provided OpenAlex ‘topics’ list)
Skeptical interpretation: topic scores in OpenAlex-style systems are model-derived and do not prove which studies are “best” or “most rigorous.” They help infer domain focus.
5) Scientific strength assessment (critical)
5.1 Likely strengths
Clinical synthesis competence is suggested by highly cited review papers on seizure prognosis and circulating biomarkers in glioblastoma .
Cross-modality thinking (clinical neurology + neuro-oncology + radiologic pattern interpretation) is visible via diagnostic/practical radiology reviews .
5.2 Rigor risks / blind spots to watch
Review-level uncertainty: reviews can encode authors’ literature selection and interpretation. Without explicit search strategy and bias assessment, review conclusions can be overly confident.
Biomarker evidence inflation: circulating biomarker fields often suffer from small cohorts, inconsistent assay/processing, and lack of external validation; a review can describe challenges, but it may not fully resolve them .
Retrospective causality limits: cohort studies in elderly glioblastoma are vulnerable to confounding by indication; causal claims must be qualified .
What would most improve confidence? Access to full texts for the cited works (methods, search strategy, inclusion criteria, statistical adjustment, and data availability). Your current prompt provides enough DOI identifiers for some works, but not the full methodological content.
6) Evidence-grade snapshot (by representative DOI works)
Important: this “evidence-grade snapshot” is not a peer-review verdict of each article’s internal quality; it is a conservative mapping based on study type cues explicitly available in your prompt and typical limitations of reviews vs retrospective cohorts.
7) Bottom-line scientific critique
Most defensible characterization: Durán-Peña’s visible portfolio (from your supplied DOI-identified works) aligns strongly with clinical neuro-oncology synthesis (epilepsy prognosis frameworks, biomarker challenges, diagnostic imaging pattern approaches) .
Rigor limitation you should actively test: if you rely on conclusions (especially in biomarker review domains), check whether the review’s claims are supported by high-quality prospective/externally validated studies rather than retrospective correlations.
Falsification mindset: the review narratives should be stress-tested by later systematic reviews, replication attempts, and assay-standardization studies; for retrospective cohorts, alternative confounder-adjusted analyses (or prospective validation) are crucial .
Quick next queries (BGPT)
Feedback:
Updated: April 29, 2026
BGPT Author Review
Scientific Quality
60%
Moderate scientific quality signal based on provided, DOI-identifiable works that are primarily clinical reviews (useful for synthesis) plus at least one retrospective cohort example. Strength: domain-focused clinical synthesis in neuro-oncology/epilepsy and biomarker challenges. Limitations: without full-text methods, review search/bias handling cannot be verified; retrospective designs are confounded by indication and selection bias. Bibliometrics (h-index~10 in your snapshot) suggest influence but not necessarily causal quality or reproducibility of primary evidence.
Communication Quality
70%
Likely clear communication given review-oriented venues and high citation counts for synthesis papers, but the prompt lacks the full text needed to judge structure, uncertainty quantification, or whether claims are appropriately hedged. Communication quality is therefore inferred only indirectly from work type and visibility.
Author Novelty
50%
Likely moderate novelty: review papers often consolidate existing evidence rather than introduce new mechanisms. Any novelty would need primary-study identification or evidence of novel frameworks derived from new data, which is not verifiable from the provided subset.
Scientific Rigor
50%
Rigor appears plausibly moderate for reviews, but key quality dimensions (search strategy, selection criteria, bias assessment, and statistical interpretation) are not provided. Retrospective cohort work carries intrinsic limitations unless strong adjustment/validation is demonstrated in full text; only study-type cue is available.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
That circulating biomarker review conclusions are directly transferable to all glioblastoma patient subgroups without assay-standardization; this is unlikely given known variability and the recurring biomarker-validation bottleneck.
That retrospective elderly glioblastoma outcome differences can be interpreted causally without careful confounding control; retrospective cohort designs typically cannot uniquely identify irradiation effects from baseline severity differences.
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Explore by Goal
Quick Explanation
Long Explanation
Ask a Follow-Up
Key Insight
Hypothesis Graveyard
Discussion